[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Zhonghua Jie He He Hu Xi Za Zhi
; 43(0): E002, 2020 Feb 05.
Article
in Chinese
| MEDLINE | ID: covidwho-309
ABSTRACT
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-ß, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
Chinese
Journal:
Zhonghua Jie He He Hu Xi Za Zhi
Year:
2020
Document Type:
Article
Affiliation country:
Cma.j.issn.1001-0939.2020.0002
Similar
MEDLINE
...
LILACS
LIS